Quarterly revenue of $658 million and Adjusted EBITDA of $58.3 million; GAAP loss of ($3.02)/share and adjusted EPS of $0.30 DALLAS, Aug. 07, 2025 (GLOBE NEWSWIRE) --  AMN Healthcare Services, Inc. (NYSE: AMN), the leader and innovator in total talent …

Net Revenue totaled $65 million and Gross Profit Margin was 51.1% from continuing operations, excluding Michigan 12th consecutive quarter of positive Cash Flow from continuing operations and 8th consecutive quarter of positive Free Cash Flow¹ Announced …

Presented updated data at ASCO showing consistency with prior data, including 10.3-month median PFS and 39% ORR in patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer Initiated Phase 3 ReDiscover-2 trial in Q2 Approximately $657 million in …

SAN CLEMENTE, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced financial results for the quarterly period ended June 30, 2025. …

… period”). “The strong second quarter results reflect the continued … ’s Chief Financial Officer. Second Quarter 2025 Highlights: (unaudited; … reported in the second quarter of 2024. Pharmacy benefit services … not reflect these capital expenditures; (3) it does …

- Discussed plans to support a pivotal Alzheimer’s disease program with FDA at end-of-phase 2 meeting - - Initiated expanded access program (EAP) for people with dementia with Lewy bodies (DLB) - - Surpassed 50% enrollment in Phase 2 ‘START’ study of …

… of 12% over Q2 2024; Q2 2025 gross profit … the International Society for Pharmacoeconomic and Outcomes Research (ISPOR … website for more presentations. Second Quarter Ended June 30, 2025 … decision-making, including managing expenditures. Period-to-period …

… business update. "The second quarter of 2025 heralded another important … in the second quarter of 2025 compared to the second quarter of 2024 … less than 20% of overall expenditures. In April 2025, the … by PARI Pharma GmbH (PARI). About PARI Pharma and the …

… VTRS) today reported strong second quarter 2025 financial results and … The "Viatris Q2 2025 Earnings Presentation," … operating activities less capital expenditures. Management uses these … tax, healthcare and pharmaceutical laws, regulations and …

Net sales for the second quarter of 2025 were $16.7 million, up 2.4% compared to $16.3 million for the second quarter of 2024 Building Supply segment sales increased by $1.1 million, or 11.5%, to $11.1 million, compared to $9.9 million for the three months …